Assuming 5% liver bioavailability in humans, an oral dosage of 15 mg per day is expected to reduce PCSK9 by 80% in a steady state, which supports the development of an oral dosage form of PCSK9 ASO for the treatment of dyslipidemia. Here, PCSK9 is linked to metabolic syndrome.